NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.01. The company earned $1.45 million during the quarter, compared to analysts' expectations of $3.56 million. View Kala Pharmaceuticals' Earnings History.

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Kala Pharmaceuticals.

4 equities research analysts have issued 1-year price targets for Kala Pharmaceuticals' shares. Their forecasts range from $9.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $21.25 in the next year. This suggests a possible upside of 431.3% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

News headlines about KALA stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Kala Pharmaceuticals.

Kala Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totalling 3,940,000 shares, an increase of 6.8% from the October 31st total of 3,690,000 shares. Based on an average daily trading volume, of 292,500 shares, the days-to-cover ratio is currently 13.5 days. Currently, 15.2% of the shares of the stock are sold short. View Kala Pharmaceuticals' Current Options Chain.

Some companies that are related to Kala Pharmaceuticals include Intra-Cellular Therapies (ITCI), Aprea Therapeutics (APRE), AC Immune (ACIU), Provention Bio (PRVB), Stemline Therapeutics (STML), Viking Therapeutics (VKTX), Magenta Therapeutics (MGTA), Morphic (MORF), Prothena (PRTA), DiaMedica Therapeutics (DMCAF), Akorn (AKRX), Frequency Therapeutics (FREQ), Dynavax Technologies (DVAX), Catalyst Pharmaceuticals (CPRX) and Molecular Templates (MTEM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Paratek Pharmaceuticals (PRTK), REDHILL BIOPHAR/S (RDHL), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Catalyst Pharmaceuticals (CPRX) and Dynavax Technologies (DVAX).

(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.62%), State Street Corp (0.93%), Point72 Asset Management L.P. (0.90%), Boston Partners (0.36%), Wedbush Securities Inc. (0.26%) and Barclays PLC (0.04%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Kala Pharmaceuticals.

KALA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., State Street Corp, Wedbush Securities Inc. and Boston Partners. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $4.00.

Kala Pharmaceuticals has a market capitalization of $138.18 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]